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ABSTRACT
OBJECTIVES The aim of this study was to evaluate 1-year outcomes of valve–in–mitral annular calciﬁcation (ViMAC) in
the MITRAL (Mitral Implantation of Transcatheter Valves) trial.
BACKGROUND The MITRAL trial is the ﬁrst prospective study evaluating the feasibility of ViMAC using balloonexpandable aortic transcatheter heart valves.
METHODS A multicenter prospective study was conducted, enrolling high-risk surgical patients with severe mitral
annular calciﬁcation and symptomatic severe mitral valve dysfunction at 13 U.S. sites.
RESULTS Between February 2015 and December 2017, 31 patients were enrolled (median age 74.5 years [interquartile
range (IQR): 71.3 to 81.0 years], 71% women, median Society of Thoracic Surgeons score 6.3% [IQR: 5.0% to 8.8%],
87.1% in New York Heart Association functional class III or IV). Access was transatrial (48.4%), transseptal (48.4%), or
transapical (3.2%). Technical success was 74.2%. Left ventricular outﬂow tract obstruction (LVOTO) with hemodynamic
compromise occurred in 3 patients (transatrial, n ¼ 1; transseptal, n ¼ 1; transapical, n ¼ 1). After LVOTO occurred in the
ﬁrst 2 patients, pre-emptive alcohol septal ablation was implemented to decrease risk in high-risk patients. No intraprocedural deaths or conversions to open heart surgery occurred during the index procedures. All-cause mortality at
30 days was 16.7% (transatrial, 21.4%; transseptal, 6.7%; transapical, 100% [n ¼ 1]; p ¼ 0.33) and at 1 year was 34.5%
(transatrial, 38.5%; transseptal, 26.7%; p ¼ 0.69). At 1-year follow-up, 83.3% of patients were in New York Heart
Association functional class I or II, the median mean mitral valve gradient was 6.1 mm Hg (IQR: 5.6 to 7.1 mm Hg), and all
patients had #1þ mitral regurgitation.
CONCLUSIONS At 1 year, ViMAC was associated with symptom improvement and stable transcatheter heart valve performance. Pre-emptive alcohol septal ablation may prevent transcatheter mitral valve replacement–induced LVOTO in patients at risk. Thirty-day mortality of patients treated via transseptal access was lower than predicted by the Society of Thoracic
Surgeons score. Further studies are needed to evaluate safety and efﬁcacy of ViMAC. (J Am Coll Cardiol Intv 2021;14:830–45)
© 2021 by the American College of Cardiology Foundation.
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P

atients with severe mitral annular calciﬁcation

Boards of the participating institutions. All

ABBREVIATIONS

(MAC) are at high risk for conventional mitral

patients provided written informed consent.

AND ACRONYMS

STUDY DESIGN AND PATIENTS. The MITRAL

CT = computed tomographic

trial early feasibility study is a physician-

IQR = interquartile range

valve (MV) surgery because they often have

multiple comorbid conditions, and the calcium burden
makes the procedure technically challenging, precluding a successful outcome for many (1–3).
Transcatheter MV replacement (TMVR) with the
off-label use of aortic balloon-expandable transcatheter heart valves (THVs) has been used as an
alternative to conventional MV surgery. Data on the
early experience with these procedures were collected
in 2 TMVR retrospective registries, which showed 25%
to 35% all-cause mortality at 30 days and 54% to 63% at
1 year (4,5). In these registries, left ventricular outﬂow
tract
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obstruction

(LVOTO)

with

hemodynamic

compromise occurred in 11% to 40% of patients and
was associated with poor outcomes. Alcohol septal
ablation was shown to reduce TMVR-induced left
ventricular outﬂow tract (LVOT) gradient acutely and
has been a lifesaving rescue option (6). Pre-emptive
use of alcohol ablation as a strategy to decrease the
risk for TMVR-induced LVOTO had not been used
prospectively before the clinical trial we describe
herein. The MAC arm of the MITRAL (Mitral Implantation of Transcatheter Valves) trial is a prospective
single-arm study, which was designed to evaluate the
safety and feasibility of TMVR with a balloonexpandable THV to treat patients with severe MAC at
high surgical risk. This trial allowed the pre-emptive
use of alcohol ablation to decrease the risk for
TMVR-induced LVOTO in patients at risk. Herein, we
present 30-day and 1-year outcomes of patients in the
MAC arm of the MITRAL trial.

initiated, prospective, multicenter clinical

LAMPOON = intentional

trial (IDE G140136; NCT02370511) designed to

laceration of the anterior mitral

evaluate the safety and feasibility of TMVR
using the SAPIEN XT and SAPIEN 3 valves

leaﬂet to prevent left
ventricular outﬂow tract
obstruction

(Edwards Lifesciences, Irvine, California). The

LVOT = left ventricular

study has 3 treatment arms: 1) native MV dis-

outﬂow tract

ease with MAC, treated with valve-in-MAC

LVOTO = left ventricular

(ViMAC) (n ¼ 31); 2) failing MV annuloplasty

outﬂow tract obstruction

ring,

MAC = mitral annular

treated

with

mitral

valve-in-ring

(n ¼ 30); and 3) failed surgical bioprostheses,
treated with mitral valve-in-valve (n ¼ 30). We

MS = mitral stenosis

report the results of the MAC arm.
Patients at high surgical risk were considered eligible for the study if they had severe
MAC with severe mitral stenosis (MS) or severe mitral regurgitation (MR) with at least
moderate MS and symptoms of New York
Heart Association

functional

class II

calciﬁcation

MR = mitral regurgitation

or

MV = mitral valve
THV = transcatheter heart
valve

TMVR = transcatheter mitral
valve replacement

ViMAC = valve–in–mitral
annular calciﬁcation

greater. Inclusion and exclusion criteria are
listed in Supplemental Appendix 1. Clinical information and cardiac imaging for study candidates were
presented in a live case-review conference call to an
eligibility committee.
During the course of the study, we observed that a
TMVR-induced LVOT gradient could recur the day
after successful alcohol septal ablation was performed to treat acute LVOTO. The suspected mechanism for recurrence was septal edema. This ﬁnding
led to the hypothesis that pre-emptive alcohol septal

SEE PAGE 873

METHODS

ablation to prevent LVOTO in patients at risk could be
a better strategy if performed days or weeks before
TMVR to avoid the acute phase, when septal edema

This study was conducted following ethical principles

may occur. After this observation was made, patients

according to the Declaration of Helsinki as well as U.S.

who were not accepted into the study because of high

Food and Drug Administration guidelines (Code of

risk for LVOTO were given the option of pre-emptive

Federal Regulations Title 21, Part 812, and Good Clin-

septal ablation with case reconsideration after follow-

ical Practices recommended by the International Or-

up computed tomographic (CT) imaging 3 to 4 weeks

ganization for Standardization [ISO 14155:2011]). The

after alcohol ablation. The outcomes of patients un-

study was approved by the Mayo Clinic Institutional

dergoing septal ablation outside the trial were not

Review Board and the respective Institutional Review

collected.
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F I G U R E 1 Cardiac Computed Tomographic Analysis

Measurements of a calciﬁed mitral annulus, made with (A) Vitrea (Vital Images, Minnetonka, Minnesota, USA), and (B) 3mensio Structural Heart Workﬂow version 8.1
(Pie Medical Imaging, Maastricht, the Netherlands). The mitral valve “neo-annulus” area measurement is shown from the surgeon’s short-axis view during diastole
(D-shape method). (C-D) A virtual THV is placed in the mitral annulus (pink), size selected according to annulus area. (E-F) Neo-LVOT measurement using Mimics,
Materialise, Leuven Belgium. (G) Virtual valve visualized in the LVOT long-axis view. The LVOT space is measured where the THV stent frame is closest to the septum
(arrow). (H) Neo-LVOT area measurement shown in short-axis view during systole. After placing the virtual valve (pink), the remaining LVOT area is measured
(arrow). (I) Fluoroscopy simulation shows a coplanar view of the mitral annulus, used to determine the valve deployment angle during valve implantation. (J) A virtual
valve is placed 80% ventricular and 20% atrial across the mitral annulus. Radiopaque landmarks such as calcium (arrow) are often used as surrogates to determine the
landing zone of the ventricular edge of the THV stent during implantation. (K,L) Images after TMVR show the THV 80% ventricular and 20% atrial across the
mitral annulus. CAU ¼ caudal; CRA ¼ cranial; RAO ¼ right anterior oblique.

Baseline echocardiographic and CT studies were

approaches were allowed. Access type was selected

analyzed by independent core laboratories. Clinical

according to anatomy, with transseptal preferred for

events were adjudicated by an independent clinical

patients with favorable anatomy.

events committee, and safety was monitored by a

Details of the delivery access type selection and

data and safety monitoring board (Supplemental

technique are provided in Supplemental Appendix 4.

Appendix 2).

OUTCOMES. The primary safety endpoint was tech-

PROCEDURES. Transthoracic

transesophageal

nical success at exit from the catheterization labora-

echocardiography were performed according to pub-

tory or operating room, deﬁned as successful delivery

lished guidelines and analyzed at an independent

and retrieval of the transcatheter delivery system,

core laboratory according to American Society of

deployment of a single valve in the correct position in

Echocardiography standards (7). The cardiac CT im-

the mitral annulus, adequate performance of the

age acquisition protocol was similar to CT protocols

transcatheter

for transcatheter aortic valve replacement (8), with

gradient <10 mm Hg and residual MR <2þ, no need

adjustments for MV analysis (9), summarized in

for surgery or additional reintervention, and patient’s

Supplemental Appendix 3 and illustrated in Figure 1.

departure from the procedure room alive. The pri-

Transseptal,

mary performance endpoint was absence of MR grade

transapical,

and

and

open

transatrial

valve

including

a
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F I G U R E 2 Patient Flowchart

DNR ¼ do not resuscitate; MAC ¼ mitral annular calciﬁcation; MOF ¼ multiple organ failure; LVOTO ¼ left ventricular outﬂow tract obstruction; STS ¼ Society of
Thoracic Surgeons; THV ¼ transcatheter heart valve; TMVR ¼ transcatheter mitral valve replacement; ViMAC ¼ valve–in–mitral annular calciﬁcation; VSD ¼ ventricular
septal defect.

2þ or greater or mean MV gradient $10 mm Hg at

indicate statistical signiﬁcance. All analyses were

30 days and 1 year. Secondary safety endpoints

conducted using R version 3.4.2 (R Foundation for

included procedural success and all-cause mortality

Statistical Computing, Vienna, Austria).

at 30 days and 1 year. Deﬁnitions and a complete list
of secondary endpoints are provided in Supplemental

RESULTS

Appendix 5.
STATISTICAL ANALYSIS. Continuous variables are

Between February 2015 and December 2017, 92 pa-

summarized as median (interquartile range [IQR]).

tients were screened and their cases presented at

Categorical variables are presented as frequencies

case-review conference calls for eligibility determi-

and percentages. Only 1 patient was treated via

nation. Of these patients, 61 were excluded because

transapical access. Therefore, we did not include this

of high risk for LVOTO (n ¼ 29), embolization (n ¼ 16),

patient’s data in the group comparison, which was

or both (n ¼ 16). These patients were not treated with

between transseptal and transatrial cases. Compari-

transatrial ViMAC, because they were not candidates

sons between discrete groups were made using the

for surgery or they refused surgery. Similarly, they

Fisher exact test. Comparisons of continuous vari-

were not treated with pre-emptive alcohol septal

ables between groups were made using Kruskal-

ablation, because of clinical or anatomic characteris-

Wallis 1-way analysis of variance on ranks. For com-

tics that made them not ideal candidates, or the local

parisons between time points, a Wilcoxon test was

site preferred other options. A total of 31 patients

used. These comparisons included only patients with

were enrolled (Figure 2). Baseline clinical character-

values at both time points. A Kaplan-Meier curve was

istics are described in Table 1. Brieﬂy, the patients’

generated for all-cause mortality, and treatment arms

median age was 74.5 years (IQR: 71.3 to 81.0 years),

were compared using the log-rank test. All p values

71% were women, and they had multiple comorbid

were 2-sided, and values <0.05 were considered to

conditions, including 51.6% with prior aortic valve
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T A B L E 1 Baseline Patient Characteristics

Total Patients*
(N ¼ 31)

Transatrial Access
(n ¼ 15)

Transseptal Access
(n ¼ 15)

p Value†

74.5 (71.3–81.0)

78.0 (73.5–81.5)

72.0 (68.5–79.5)

0.22

Female

22/31 (71.0)

12/15 (80.0)

9/15 (60.0)

0.43

Diabetes

12/31 (38.7)

7/15 (46.7)

5/15 (33.3)

0.71

Atrial ﬁbrillation

13/31 (41.9)

7/15 (46.7)

6/15 (40.0)

1.00
0.43

Age (yrs)

Chronic kidney disease

9/31 (29.0)

3/15 (20.0)

6/15 (40.0)

Chronic obstructive pulmonary disease

15/31 (48.4)

6/15 (40.0)

8/15 (53.3)

0.72

Home oxygen therapy

7/31 (22.6)

2/15 (13.3)

4/15 (26.7)

0.65

Receiving long-term anticoagulation

9/31 (29.0)

2/15 (13.3)

7/15 (46.7)

0.11

Hospitalization for heart failure during prior 12 months

14/31 (45.2)

8/15 (53.3)

6/15 (40.0)

0.72
0.60

Prior stroke

4/31 (12.9)

3/15 (20.0)

1/15 (6.7)

Prior CABG

12/31 (38.7)

6/15 (40.0)

6/15 (40.0)

1.00

Prior AVR
TAVR
SAVR

16/31 (51.6)
3/16 (18.8)
13/16 (81.3)

8/15 (53.3)
2/8 (25.0)
6/8 (75.0)

8/15 (53.3)
1/8 (12.5)
7/8 (87.5)

1.00
1.00
1.00

Prior MV balloon valvuloplasty
STS score for MVR
NYHA functional class
I
II
III
IV

4/31 (12.9)

1/15 (6.7)

3/15 (20.0)

0.60

6.3 (5.0–8.8)

6.4 (5.4–8.8)

6.2 (4.8–8.7)

0.82

0/31 (0.0)
4/31 (12.9)
22/31 (71.0)
5/31 (16.1)

0/15 (0.0)
4/15 (26.7)
11/15 (73.3)
0/15 (0.0)

0/15 (0.0)
0/15 (0.0)
11/15 (73.3)
4/15 (26.7)

0.01

Values are median (interquartile range) or n/N (%). *Includes 1 transapical case not shown in transatrial or transseptal column. †Transatrial versus transseptal.
AVR ¼ aortic valve replacement; CABG ¼ coronary artery bypass grafting; MV ¼ mitral valve; MVR ¼ mitral valve replacement; NYHA ¼ New York Heart Association;
SAVR ¼ surgical aortic valve replacement; STS ¼ Society of Thoracic Surgeons; TAVR ¼ transcatheter aortic valve replacement.

T A B L E 2 Baseline Echocardiographic Characteristics

All Patients*
(N ¼ 31)

Transatrial Access
(n ¼ 15)

Transseptal Access
(n ¼ 15)

p Value†

0.66

Ejection fraction (%)

63.1 (55.1–66.9)

64.8 (57.6–67.1)

61.3 (52.6–66.4)

Stroke volume (ml)

59.5 (49.2–80.5)

76.1 (54.9–86.8)

55.0 (48.9–70.7)

0.16

4.6 (3.7–6.2)

4.7 (4.2–6.7)

4.2 (3.7–6.0)

0.46

10.0 (7.6–12.8)

8.1 (7.3–11.8)

11.1 (8.2–13.9)

0.17

2.3 (1.8–2.9)

2.4 (1.7–3.2)

2.1 (1.8–2.5)

0.55

Cardiac output (l/min)
Mean MVG (mm Hg)
MVA (cm2)‡

53.1 (45.0–66.0)

53.5 (51.9–72.2)

49.7 (44.7–56.2)

0.31

Peak LVOT gradient (mm Hg)

Pulmonary artery systolic pressure (mm Hg)§

4.5 (3.1–6.9)

5.5 (2.8–7.9)

4.4 (3.6–6.8)

0.76
0.97

Mean LVOT gradient (mm Hg)

2.7 (1.7–3.9)

2.9 (1.5–4.2)

2.4 (2.0–3.7)

Mitral valve pathology
Stenosis (1 transapical)
Regurgitation
Both stenosis and regurgitation

23/31 (74.2)
3/31 (9.7)
5/31 (16.1)

9/15 (60.0)
3/15 (20.0)
3/15 (20.0)

13/15 (86.7)
0/15 (0.0)
2/15 (13.3)

Severity of mitral regurgitation
None or trace (1 transapical)
1 (þ)
2 (þ)
3 (þ)
4 (þ)

6/31 (19.4)
11/31 (35.5)
4/31 (12.9)
8/31 (25.8)
2/31 (6.4)

2/15 (13.3)
2/15 (13.3)
3/15 (20.0)
7/15 (46.7)
1/15 (6.7)

3/15 (20.0)
9/15 (60.0)
1/15 (6.7)
1/15 (6.7)
1/15 (6.7)

0.10

0.02

Values are median (interquartile range) or n/N (%). *Includes 1 transapical case not shown in the transatrial or transseptal column. †Transatrial versus transseptal. ‡Uncertain
reliability; echocardiographic methods validated in rheumatic disease and not mitral annular calciﬁcation. §7 missing values.
LVOT ¼ left ventricular outﬂow tract; MVA ¼ mitral valve area; MVG ¼ mitral valve gradient.
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T A B L E 3 Intraprocedural Results

All Patients*
(N ¼ 31)

Transatrial Access
(n ¼ 15)

Transseptal Access
(n ¼ 15)

Device
SAPIEN XT (1 transapical)
SAPIEN 3

2/31 (6.5)
29/31 (93.5)

0/15 (0.0)
15/15 (100.0)

1/15 (6.7)
14/15 (93.3)

Device size
23 mm
26 mm (1 transapical)
29 mm

3/31 (9.7)
9/31 (29.0)
19/31 (61.3)

2/15 (13.3)
2/15 (13.3)
11/15 (73.3)

1/15 (6.7)
6/15 (40.0)
8/15 (53.3)

Access
Transapical
Direct open transatrial
Transseptal
Traditional (wire free in left ventricle)
Modiﬁed (wire externalized through percutaneous sheath in left ventricle)

1/31 (3.2)
15/31 (48.4)
15/31 (48.4)
14/15 (93.3)
1/15 (6.7)

0/15 (0.0)
15/31 (48.4)
0/15 (0.0)
0/15 (0.0)
0/15 (0.0)

0/15 (0.0)
0/15 (0.0)
15/31 (48.4)
14/15 (93.3)
1/15 (6.7)

Pre-dilation or balloon sizing

6/31 (19.4)

2/15 (13.3)

4/15 (26.7)

14/31 (45.2)
17/31 (54.8)
3.0 (0.0–4.0)

7/15 (46.7)
8/15 (53.3)
3.0 (0.0–4.0)

7/15 (46.7)
8/15 (53.3)
4.0 (2.0–6.0)

0.07

Post-dilation (none in transapical)

10/31 (32.3)

2/15 (13.3)

8/15 (53.3)

0.05

Septostomy closed in transseptal cases during index procedure‡

3/15 (20.0)

0/15 (0.0)

3/15 (20.0)

1.00

5/31 (16.1)
4/31 (12.9)
1/31 (3.2)
23/31 (74.2)
3/31 (9.7)
1/31 (3.2)
4/31 (12.9)
1/31 (3.2)
1/31 (3.2)
1/31 (3.2)
5/31 (16.7)
0/31 (0.0)
0/31 (0.0)
0/31 (0.0)
0/31 (0.0)
1/31 (3.2)

3/15 (20.0)
2/15 (13.3)
1/15 (6.7)
11/15 (73.3)
1/15 (6.7)
0/15 (0.0)
2/15 (13.3)
1/15 (6.7)
0/15 (0.0)
1/15 (6.7)
2/15 (13.3)
0/15 (0.0)
0/15 (0.0)
0/15 (0.0)
0/15 (0.0)
0/15 (0.0)

1/15 (6.7)
1/15 (6.7)
0/15 (0.0)
12/15 (80.0)
1/15 (6.7)
1/15 (6.7)
1/15 (6.7)
0/15 (0.0)
1/15 (6.7)
0/15 (0.0)
2/15 (13.3)
0/15 (0.0)
0/15 (0.0)
0/15 (0.0)
0/15 (0.0)
0/15 (0.0)

0.60
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
NA
NA
NA
NA
NA

2.8 (2.1–3.8)
3.2 (2.7–3.4)
6.3 (4.2–8.8)
3.5 (2.1–4.5)

2.8 (2.1–3.9)
2.7 (2.6–3.5)
6.5 (4.8–10.9)
3.0 (2.3–4.8)

2.7 (2.2–3.5)
3.2 (3.0–3.4)
6.3 (4.2–7.0)
3.6 (1.9–3.7)

0.61
0.21
0.50
0.82
1.00

10/31 (32.3)
17/31 (54.8)
3/31 (9.7)
1/31 (3.2)

5/15 (33.3)
8/15 (53.3)
2/15 (13.3)
0/15 (0.0)

5/15 (33.3)
9/15 (60.0)
1/15 (6.7)
0/15 (0.0)

14/31
14/31
2/31
1/31

8/15 (53.3)
6/15 (40.0)
1/15 (6.7)
0/15 (0.0)

6/15 (40.0)
8/15 (53.3)
1/15 (6.7)
0/15 (0.0)

Additional contrast during initial deployment
No
Yes (1 transapical)
Additional contrast volume, ml

Results
In-hospital mortality (1 transapical)
Cardiovascular (1 transapical)
Noncardiovascular
Technical success at exit from catheterization lab
LVOTO with hemodynamic compromise
Need for a second valve§
$2 (þ) residual MR (1 transapical)
LV perforation
Pericardial effusion requiring pericardiocentesis
Ventricular septal defect (myectomy in transatrial TMVR)
New pacemaker requirement (1 transapical)
Valve embolization
Conversion to open heart surgery
Paravalvular leak closure
Myocardial infarction requiring intervention
Major vascular complications (1 transapical)
Echocardiographic characteristics post-TMVR
Mean MVG (mm Hg)
MVA (cm2)
Peak LVOT gradient (mm Hg)‡
Mean LVOT gradient (mm Hg)||
Residual total MR
Trace or none
1 (þ)
2 (þ)
$3 (þ) (1 transapical)
Amount of paravalvular MR
Trace or none
1 (þ)
2 (þ)
$3 (þ) (1 transapical)

p Value†

1.00

0.39

NA

0.65
1.00

0.89
(45.2)
(45.2)
(6.5)
(3.2)

Values are n/N (%) or median (interquartile range). *Includes 1 transapical case not shown in transatrial or transseptal column. †Transatrial vs. transseptal. ‡1 for hypoxemia due to a right-toleft shunt and 2 for signiﬁcant left-to-right shunts at the discretion of the operator. All Amplatzer Septal Occluder device. §Due to excessive atrial positioning causing mitral regurgitation.
||10 missing values.
LV ¼ left ventricular; LVOTO ¼ left ventricular outﬂow tract obstruction; MR ¼ mitral regurgitation; NA ¼ not applicable; TMVR ¼ transcatheter mitral valve replacement; other abbreviations as in Tables 1 and 2.
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were LVOTO, MR $2þ, and need for a second valve.

T A B L E 4 Baseline Echocardiographic Characteristics of Patients Treated With

There were no cases of valve embolization, need for

Transseptal Access After Implementing Preemptive ASA (n ¼ 14)

conversion to open heart surgery, or deaths during
Trans-septal

the index procedures. The median hospital stay was

No ASA (n ¼ 7)

ASA (n ¼ 7)

p Value

Ejection fraction (%)

65.0 (57.1–69.0)

55.6 (52.6–60.0)

0.44

There were 5 in-hospital deaths (16.1%), which

Stroke volume (ml)

55.6 (50.0–70.6)

55.0 (48.8–73.9)

0.92

included 3 patients who were treated via transatrial

Cardiac output (l/min)

8.5 days (IQR: 4.25 to 12.75 days).

5.7 (3.7–5.7)

4.2 (3.8–6.2)

0.47

access (3 of 15 [20%]). One patient who underwent

12.3 (7.7–18.0)

10.6 (9.4–11.3)

0.57

transapical access died. The case was complicated by

1.9 (1.8–2.2)

2.5 (2.0–2.8)

0.28

LVOTO, and the patient was treated the following day

62.0 (53.8–68.5)

44.2 (34.8–46.5)

0.01

with surgical explantation of the THV and redo

Peak LVOT gradient (mm Hg)

4.5 (4.0–6.8)

4.6 (2.6–8.2)

0.89

ViMAC with transatrial access and surgical resection

Mean LVOT gradient (mm Hg)

2.7 (2.1–3.7)

2.6 (1.5–4.5)

1.00

of the anterior leaﬂet. The other remaining in-

0.46

hospital death was the ﬁrst patient treated in the

Mean MVG (mm Hg)
MVA (cm2)*
Pulmonary artery systolic pressure (mm Hg)†

Mitral valve pathology
Stenosis
Regurgitation
Both stenosis and regurgitation
Severity of mitral regurgitation
None or trace
1 (þ)
2 (þ)
3 (þ)
4 (þ)

5 (71.4)
0 (0.0)
2 (28.6)

7 (100.0)
0 (0.0)
0 (0.0)

trial. That patient underwent transseptal ViMAC (1 of
15 [6.7%]) (p ¼ 0.60) and had LVOTO with hemody0.27

0 (0.0)
6 (85.7)
0 (0.0)
0 (0.0)
1 (14.3)

2 (28.6)
3 (42.9)
1 (14.3)
1 (14.3)
0 (0.0)

Values are median (interquartile range) or n/N (%). *Uncertain reliability; echocardiographic methods validated in
rheumatic disease and not mitral annular calciﬁcation. †3 missing.
ASA ¼ alcohol septal ablation; other abbreviations as in Table 2.

namic compromise, as detailed later.
LVOTO

AND

PRE-EMPTIVE

ALCOHOL

SEPTAL

ABLATION. LVOTO with hemodynamic compromise

occurred in 3 patients (transseptal, n ¼ 1; transapical,
n ¼ 1; transatrial, n ¼ 1). Outcomes of these patients
are summarized in Supplemental Appendix 6.
After the second patient was treated in this trial, we
began to use pre-emptive alcohol septal ablation in
patients at risk for TMVR-induced LVOTO. Seven of the

replacement. The median Society of Thoracic Surgeons Predicted Risk of Mortality score was 6.3%
(IQR: 5.0% to 8.8%) with a mean of 8.6  8.2%
(transatrial 7.8  4.2%, transseptal 9.9  11.0%),
p ¼ 0.50), and most patients were in New York Heart
Association functional class III or IV (transatrial,
73.3%; transseptal, 100%; p ¼ 0.01). Baseline echocardiographic characteristics are described in Table 2.
Left ventricular function was normal. MS was the
predominant pathology and was present in 74.2%.
Transseptal access was used for 15 patients
(48.4%), transatrial for 15 patients (48.4%), and
transapical for 1 patient (3.2%). Selection of transatrial access was based on the risk for embolization
(n ¼ 6), risk for LVOTO (n ¼ 3), or both (n ¼ 6). One
patient was treated via transapical access because of

remaining 14 patients treated with transseptal access
were at high risk for LVOTO (median neo-LVOT area
100.0 mm 2; IQR: 87.9 to 145.0 mm 2) and underwent
pre-emptive alcohol septal ablation using 1.0 ml (IQR:
0.65 to 2.0 ml) of alcohol. Baseline echocardiographic
characteristics of these patients are summarized in
Table 4. Repeat CT scans 45 days (IQR: 23 to 50 days)
after alcohol septal ablation showed decreased risk
(median neo-LVOT area 227.5 mm 2; IQR: 215.5 to
311.2 mm 2), and all underwent successful transseptal
ViMAC (Figure 3). Three of the patients treated via
transatrial access also underwent pre-emptive alcohol
septal ablation (median 1.6 ml; IQR: 1.1 to 2.0 ml)
before transatrial ViMAC (median neo-LVOT area
50.9 mm 2; IQR: 0 to 119.3 mm2 ) to avoid the need for
surgical myectomy during the same procedure.

challenging anatomy for transseptal access. Proce-

ADDITIONAL ENDPOINTS. The primary performance

dural results are shown in Table 3.

endpoint was achieved for 88% of survivors at

PRIMARY SAFETY ENDPOINTS AND ACUTE RESULTS.

The primary safety endpoint of technical success at
exit from the procedure room was 74.2% (transatrial,
73.3% [11 of 15]; transseptal, 80.0% [12 of 15];
p ¼ 1.00). Reasons for not meeting technical success
criteria in 4 transatrial cases included LVOTO,
MR $2þ, wire-induced left ventricular perforation,

30 days (22 of 25) and for 100% of patients alive who
had echocardiographic data available (18 of 18) at 1
year. All-cause mortality at 30 days was 16.7%
(transatrial, 21.4%; transseptal, 6.7%; p ¼ 0.33) and at
1 year was 34.5% (transatrial, 38.5% [5 of 13]; transseptal, 26.7% [4 of 15]; p ¼ 0.69). Kaplan-Meier survival curves are shown in the Central Illustration.

and ventricular septal defect due to concomitant

THIRTY-DAY OUTCOMES. At 30 days, 25 of 30 pa-

surgical myectomy. Reasons in the 3 transseptal cases

tients (83.3%) were alive, and 60% were in New York
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F I G U R E 3 Cardiac CT Findings After Pre-Emptive Alcohol Septal Ablation and Transseptal Valve-in-MAC

(A) Baseline cardiac computed tomographic (CT) imaging shows thick septum (arrow). (B) After placement of a 29-mm virtual valve, the remaining space in the LVOT is
reduced (arrow). (C) Baseline neo-LVOT area during systole is 176 mm2. CT scan obtained 4 weeks after alcohol septal ablation shows (D) reduced thickness of the
basal septum (arrow), (E) residual space in the LVOT larger than baseline, and (F) predicted neo-LVOT area during systole of 250 mm2. (G) Fluoroscopy of a transseptal
ViMAC implantation using a 29-mm SAPIEN 3 valve prepared with 4 ml of additional contrast to ﬂare the ventricular edge of the THV stent (yellow arrow), 80%
ventricular and 20% atrial in relation to the mitral annulus (white arrow). (H) CT image post-TMVR shows the SAPIEN 3 valve in the desired position. (I) Post-TMVR
CT image shows the actual neo-LVOT measurement of 182 mm2 (arrow). Abbreviations as in Figure 1 and 2.

Heart Association functional class I or II. Clinical

(65.5%) were alive (transatrial, 61.5%; transseptal,

outcomes at 30 days are shown in Table 5 and echo-

73.3%; p ¼ 0.69), and 83.3% were in New York Heart

cardiographic characteristics in Table 6. New-onset

Association functional class I or II (transatrial, 87.5%;

acute kidney injury requiring new hemodialysis and

transeptal, 80%; p ¼ 0.16).

new-onset atrial ﬁbrillation were more frequent in

Clinical outcomes at 1 year are summarized in

transatrial cases (both 28.6% vs. 0%; p ¼ 0.04). The

Table 7 and echocardiographic characteristics in

need for blood transfusion in all transatrial cases was

Table 8. Patients alive had signiﬁcant improvements

procedure related, whereas the reason for blood

in New York Heart Association functional class

transfusion in the 6 transseptal cases was hemolytic

(Central Illustration), distance walked in the 6-min

anemia (n ¼ 3) and gastrointestinal bleeding (n ¼ 3).

walk test (Figure 4), and quality-of-life scores

1-YEAR OUTCOMES. At 1-year follow-up (median 1.0

dian mean MV gradient of 6.4 mm Hg (IQR: 4.2 to

year; IQR: 1.0 to 1.2 year), 19 of 29 eligible patients

7.4 mm Hg) in transatrial cases and 6.1 mm Hg (IQR:

(Figure 5). THV function remained stable, with a me-
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C E NT R AL IL L U STR AT IO N 30-Day and 1-Year Outcomes of Valve–in–Mitral Annular Calciﬁcation in the Mitral
Implantation of Transcatheter Valves Trial

Guerrero, M. et al. J Am Coll Cardiol Intv. 2021;14(8):830–45.

Early and late outcomes for functional capacity (New York Heart [NYHA] Association functional class) in the transatrial group (left) and transseptal group (right) and
for survival (middle). ViMAC ¼ valve–in–mitral annular calciﬁcation.

5.7 to 6.8 mm Hg) in transeptal cases (p ¼ 0.93)

Appendix 7. There were no late device embolization

(Figure 6), and all patients had 1þ or less total MR.

or migration events or endocarditis.

Five patients developed hemolytic anemia by 1
year (transatrial, 7.7% [1 of 13]; transseptal, 26.7% [4

DISCUSSION

of 15]; p ¼ 0.33). Three patients with trace paravalvular leak developed hemolysis within 30 days.

This is the ﬁrst prospective, multicenter, early feasi-

One of these patients was treated with mitral valve-

bility clinical trial with independent imaging core

in-valve.

spontaneously

laboratories and independent clinical events adjudi-

resolved in 2 patients, but they required transfusion.

cation to evaluate the safety and feasibility of ViMAC

Of the 2 additional patients who developed hemolysis

using balloon-expandable aortic THVs. The following

after 30 days, 1 was treated by paravalvular leak

were the main ﬁndings: 1) transseptal ViMAC in

closure, and 1 was treated conservatively.

carefully selected patients was associated with 30-

The

paravalvular

leak

The anticoagulation regimens and valve throm-

day mortality lower than predicted by the Society of

bosis summaries are described in Supplemental

Thoracic Surgeons score; 2) pre-emptive alcohol
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T A B L E 5 30-Day Clinical Outcomes

All-cause mortality (1 transapical)
Cardiovascular (1 transapical)
Noncardiovascular

All Patients*
(N ¼ 30)

Transatrial Access†
(n ¼ 14)

5/30 (16.7)
4/30 (13.3)
1/30 (3.3)

3/14 (21.4)
2/14 (14.3)
1/14 (7.1)

Transseptal Access
(n ¼ 15)
p Value‡

1/15 (6.7)
1/15 (6.7)
0/15 (0.0)

0.33
0.60
0.48

Device success

17/30 (56.7)

9/14 (64.3)

8/15 (53.3)

0.71

Procedural success

16/30 (53.3)

9/14 (64.3)

7/15 (46.7)

0.46

Primary performance endpoint in survivors at 30 days§

22/25 (88.0)

10/11 (90.9)

12/14 (85.7)

1.00

Stroke|| (1 transapical)
Ischemic (1 transapical)
Hemorrhagic

2/30 (6.7)
2/30 (6.7)
0/30 (0.0)

1/14 (7.1)
1/14 (7.1)
0/14 (0.0)

0/15 (0.0)
0/15 (0.0)
0/15 (0.0)

0.48
0.48
NA

Myocardial infarction requiring revascularization

0/30 (0.0)

0/14 (0.0)

0/15 (0.0)

NA

Mitral valve reintervention after index procedure (MViV)¶ (1 transapical)

2/30 (6.7)

0/14 (0.0)

1/15 (6.7)

1.00

Septostomy closed in transseptal cases (3 during index procedure, 1 after index
procedure)

4/15 (26.7)

NA

4/15 (26.7)

NA

Acute kidney injury requiring hemodialysis (1 transapical)

5/30 (16.7)

4/14 (28.6)

0/15 (0.0)

0.04

Blood transfusion (1 transapical)

16/30 (53.3)

9/14 (64.3)

6/15 (40.0)

0.27

1/30 (3.3)

0/14 (0.0)

0/15 (0.0)

NA

New permanent pacemaker requirement (1 transapical)

5/30 (16.7)

2/14 (14.3)

2/15 (13.3)

1.00

New-onset atrial ﬁbrillation (1 transapical)

5/30 (16.7)

4/14 (28.6)

0/15 (0.0)

0.04

New rehospitalization for heart failure

4/30 (13.3)

1/14 (7.1)

3/15 (20.0)

0.60

Major vascular complication (1 transapical)

Device embolization or migration

0/30 (0.0)

0/14 (0.0)

0/15 (0.0)

Hemolytic anemia#

3/30 (10.0)

0/14 (0.0)

3/15 (20.0)

0.22

Valve thrombosis

0/30 (0.0)

0/14 (0.0)

0/15 (0.0)

NA

Endocarditis

0/30 (0.0)

0/14 (0.0)

0/15 (0.0)

New York Heart Association functional class
I
II
III
IV

NA
0.33

6/25 (24.0)
9/25 (36.0)
8/25 (32.0)
2/25 (8.0)

2/11 (18.2)
6/11 (54.5)
2/11 (18.2)
1/11 (9.1)

4/14 (28.6)
3/14 (21.4)
6/14 (42.9)
1/14 (7.1)

Values are n/N (%). *Includes 1 transapical case not shown in the transatrial or transseptal column. †1 withdrew consent at 8 days post-TMVR before discharge to physical
therapy center. ‡Transatrial vs. transseptal. §Reason for not meeting performance endpoint was mean mitral valve gradient of 10.2 mm Hg in a transatrial case as well as MR 2
(þ) and 3 (þ) in 2 transseptal cases. ||All during index hospitalization. ¶1 transseptal MViV for hemolytic anemia in a transseptal case and 1 transatrial valve-in-MAC for left
ventricular outﬂow tract obstruction and paravalvular leakage in the transapical case. #1 treated with MViV and 2 spontaneously resolved, but all required transfusion.
MAC ¼ mitral annular calciﬁcation; MViV ¼ mitral valve–in–valve; NA ¼ not applicable.

septal ablation preformed 3 to 4 weeks before ViMAC

MORTALITY. At 1 year, all-cause mortality in the

can prevent LVOTO during transseptal ViMAC in pa-

entire cohort was 34.5%, lower than that reported in

tients at high risk; 3) THVs performed adequately in

prior registries (4,5). For patients treated via trans-

most patients, and these outcomes were maintained

septal access, 1-year all-cause mortality was 26.7%.

at 1 year; and 4) ViMAC was associated with signiﬁ-

This is a remarkable improvement from the 51.1%

cantly diminished symptoms, improved 6-min walk

mortality rate for transseptal cases in the TMVR in

distance, and improved quality-of-life scores.

MAC Global Registry (4) and is similar to 1-year

Our results differ from those of prior retrospective

mortality for transcatheter MV edge-to-edge repair

studies that showed ViMAC to be feasible but asso-

procedures with the MitraClip (Abbott Vascular,

ciated with procedural complications and high 30-day

Santa Clara, California) reported for the United

and 1-year mortality (4,5). Outcomes for our patients

States (10).

improved signiﬁcantly with careful patient selection

Compared with the outcomes of TMVR studies

and strategies to decrease risk for TMVR-induced

evaluating THVs designed for the MV, the 30-day

LVOTO, such as pre-emptive alcohol septal ablation

(6.7%) and 1-year (26.7%) all-cause mortality rates of

performed weeks before transseptal ViMAC or surgi-

transseptal ViMAC cases in this study were identical

cal resection of the anterior leaﬂet during transatrial

to the 30-day (6%) and 1-year (26%) mortality rates

ViMAC.

reported for the initial feasibility study of the
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T A B L E 6 Echocardiographic Characteristics at 30 Days

All Patients*
(N ¼ 25)

Transatrial Access
(n ¼ 11)

Transseptal Access
(n ¼ 14)

p Value†

Ejection fraction (%)

55.5 (50.7–66.2)

55.0 (48.9–65.3)

56.0 (51.5–66.2)

0.49

Stroke volume (ml)

0.14

65.3 (46.3–76.2)

76.4 (46.3–85.9)

62.3 (48.7–70.6)

Cardiac output (l/min)

5.1 (3.8–6.0)

5.6 (4.9–7.0)

4.9 (3.4–5.4)

0.11

Mean MVG (mm Hg)

6.0 (5.2–7.8)

7.4 (5.0–8.6)

5.9 (5.3–7.1)

0.44

MVA (cm2)‡
Pulmonary artery systolic pressure (mmHg)§

2.9 (2.5–3.3)

2.9 (2.6–3.1)

2.9 (2.5–3.4)

0.89

50.5 (41.6–69.9)

42.0 (38.9–64.0)

54.2 (47.9–70.3)

0.425

Peak LVOT gradient

7.2 (4.8–11.6)

7.2 (5.9–11.7)

6.8 (4.5–11.0)

0.41

Mean LVOT gradient

3.5 (2.7–6.1)

3.2 (3.1–6.8)

3.7 (2.6–6.0)

0.83

Severity of total mitral regurgitation
None to trace
1 (þ)
2 (þ)
$3 (þ)

17/25 (68.0)
6/25 (24.0)
1/25 (4.0)
1/25 (4.0)

8/11 (72.7)
3/11 (27.3)
0/11 (0.0)
0/11 (0.0)

9/14 (64.3)
3/14 (21.4)
1/14 (7.1)
1/14 (7.1)

Severity of paravalvular mitral regurgitation
None to trace
1 (þ)
2 (þ)
$3 (þ)

20/25 (80.0)
3/25 (12.0)
1/25 (4.0)
1/25 (4.0)

11/11 (100.0)
0/11 (0.0)
0/11 (0.0)
0/11 (0.0)

9/14 (64.3)
3/14 (21.4)
1/14 (7.1)
1/14 (7.1)

1.00

0.15

Values are median (interquartile range) or n/N (%). *At 30 days, 25 echocardiographic studies were available (5 patients died and 1 withdrew consent 8 days after valve-inMAC). †Transatrial vs. transseptal. ‡Uncertain reliability; standard echocardiographic methods are validated in rheumatic disease and not MAC or after TMVR. §8 missing values.
Abbreviations as in Tables 2, 3, and 5.

Tendyne transcatheter valve system (Abbott Struc-

pre-emptive alcohol septal ablation 3 to 4 weeks

tural Heart, Santa Clara, California) (11) and similar to

before TMVR. All of these patients underwent suc-

or lower than the initial experience with the Intrepid

cessful transseptal ViMAC and were alive at 30 days.

TMVR system (Medtronic, Redwood City, California),

The LAMPOON procedure (intentional laceration of

which reported 30-day mortality of 14% and 1-year

the anterior mitral leaﬂet to prevent LVOTO) was

mortality of 23.8% (12). However, these early feasi-

developed after the MITRAL trial started and was not

bility studies involved different patient populations

used in this study. The 30-day mortality of patients

with mostly functional MR in noncalciﬁed MVs. Tak-

who had transseptal access in our study was lower

ing into consideration that the MITRAL trial is an

than the 13.3% mortality of transseptal ViMAC re-

early experience with a small number of patients,

ported in the LAMPOON (Intentional Laceration of

achieving 1-year mortality similar to that shown for a

the Anterior Mitral Leaﬂet to Prevent Left Ventricular

well-established and safe procedure such as trans-

Outﬂow

catheter edge-to-edge MV repair or early experience

Mitral Valve Implantation) trial (13). The number of

with TMVR is encouraging and demonstrates this to

patients in these studies is small, therefore, mean-

be a treatment option for at least some patients in a

ingful comparisons cannot be made.

group that is otherwise difﬁcult to treat.

Tract

ACCESS TYPE

Obstruction

SELECTION

During Transcatheter

PROCESS. Transseptal

LVOTO AND THE ROLE OF PRE-EMPTIVE ALCOHOL

access was preferred in patients with favorable anat-

SEPTAL ABLATION. The new concept of performing

omy who were considered to have low risk for valve

pre-emptive alcohol septal ablation before TMVR was

embolization and LVOTO. Risk for valve embolization

instituted in this trial. We had previously described

was assessed by analysis of calcium amount and dis-

the role of emergency percutaneous alcohol septal

tribution on cardiac CT imaging. This assessment was

ablation for acutely reducing TMVR-induced LVOTO,

initially descriptive. During the course of our study

which can be a lifesaving strategy (6). After imple-

and using data from the TMVR in MAC registry for

menting pre-emptive alcohol septal ablation to

validation, a cardiac CT score was developed to

decrease the risk for LVOTO in patients at risk (after

categorize MAC severity and predict valve emboliza-

the ﬁrst 2 patients enrolled), 7 of the remaining 14

tion. A MAC score of 6 or less was associated with a

patients treated via transseptal access were consid-

very high (60%) risk for valve embolization or

ered to have a high risk for LVOTO and underwent

migration (14). A MAC score of 7 or greater and a
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T A B L E 7 1-Year Clinical Outcomes

All Patients*
(N ¼ 29)

Transatrial Access†
(n ¼ 13)

Transseptal Access
(n ¼ 15)
p Value‡

All-cause mortality (1 transapical)
Cardiovascular (1 transapical)
Noncardiovascular

10/29 (34.5)
6/29 (20.7)
4/29 (13.8)

5/13 (38.5)
3/13 (23.1)
2/13 (15.4)

4/15 (26.7)
2/15 (13.35)
2/15 (13.35)

0.69
1.00
0.58

Primary performance endpoint in survivors at 1 yr (1 missed echocardiography
study)

18/18 (100)

8/8 (100)

10/10 (100)

1.00

Stroke§ (1 transapical)
Ischemic (1 transapical)
Hemorrhagic

2/29 (6.9)
2/29 (6.9)
0/29 (0.0)

1/13 (7.7)
1/13 (7.7)
0/13 (0.0)

0/15 (0.0)
0/15 (0.0)
0/15 (0.0)

0.46
0.46
NA

Myocardial infarction requiring revascularization

0/29 (0.0)

0/13 (0.0)

0/15 (0.0)

NA

Mitral valve reintervention after index procedure (1 transapical)||

4/29 (13.8)

1/13 (7.7)

2/15 (13.3)

1.00

Septostomy closed in transseptal cases (3 during index procedure, 2 after index
procedure)

5/15 (33.3)

NA

5/15 (33.3)

NA

Acute kidney injury requiring hemodialysis (1 transapical)

5/29 (17.2)

4/13 (30.8)

0/15 (0.0)

0.01

Blood transfusion (1 transapical)

17/29 (62.1)

9/13 (76.9)

7/15 (46.7)

0.14

Major vascular complication (1 transapical)

1/29 (3.4)

0/13 (0.0)

0/15 (0.0)

NA

New permanent pacemaker requirement (1 transapical)

5/29 (17.2)

2/13 (15.3)

2/15 (13.3)

1.00

New-onset atrial ﬁbrillation (1 transapical)

5/29 (17.2)

4/13 (30.7)

0/15 (0.0)

0.07

New rehospitalization for heart failure¶

11/29 (37.9)

4/13 (30.8)

7/15 (46.7)

0.46

0/29 (0)

0/13 (0.0)

0/15 (0.0)

NA

5/29 (17.2)

1/13 (7.7)

4/15 (26.7)

0.33
1.00

Device embolization or migration
Hemolytic anemia#
Valve thrombosis

1/29 (3.4)

0/13 (0.0)

1/15 (6.7)

Endocarditis

0/29 (0.0)

0/13 (0.0)

0/15 (0.0)

New York Heart Association functional class**
I
II
III
IV

NA
0.16

7/18 (38.9)
8/18 (44.4)
3/18 (16.7)
0/18 (0.0)

2/8 (25.0)
5/8 (62.5)
1/8 (12.5)
0/8 (0.0)

5/10 (50.0)
3/10 (30.0)
2/10 (20.0)
0/10 (0.0)

Values are n/N (%). *Includes 1 transapical case not shown in the transatrial or transseptal column. †1 withdrew consent at 8 days after transatrial ViMAC before discharge to a
physical therapy center, and 1 withdrew consent at day 187 after transatrial ViMAC. ‡Transatrial vs. transseptal. §All during index hospitalization. ||2 within 30 days:
1 transseptal MViV for hemolysis and 1 transatrial valve-in-MAC for left ventricular outﬂow tract obstruction and paravalvular leakage after transapical ViMAC. 2 after 30 days:
both paravalvular leak closures (1 transatrial and 1 transseptal case). ¶The reason for heart failure was identiﬁed as volume overload in patients with pre-existing systolic
dysfunction in 1 and diastolic dysfunction in 3 of the transatrial cases. The reason in transseptal cases was diastolic heart failure in 3, aortic stenosis in 1, and mild paravalvular
leak in 1. It was thought to be attributable to persistent septostomy in 2 patients who underwent closure of an atrial septal defect during that admission. #3 cases at 30 days:
1 patient was treated with MViV, and 2 patients had spontaneous resolution, but all required transfusion. There were 2 additional cases of hemolytic anemia after 30 days: 1 was
treated with paravalvular closure and 1 conservatively. **1 missing value (1 patient alive at 1 year did not have a 1-year follow-up visit).
ViMAC ¼ valve-in-MAC; other abbreviations as in Tables 3 and 5.

neo-LVOT >190 mm2 were the main criteria for

small paravalvular leak jets contributed to hemolysis

selecting transseptal access in our study.

events in these patients. This hemolysis rate is higher

OTHER INTRAPROCEDURAL CHALLENGES. In contrast

to results from prior registries, no cases of valve
embolization occurred in this trial. In a registry report
by Yoon et al. (5), the valve embolization rate was
6.9%, and in the TMVR in MAC Global Registry, it was
4.3% (4). We attribute the absence of valve embolization in our study to careful cardiac CT analysis and

than the 3.8% rate reported in the TMVR in MAC
Global Registry, and it was not reported by Yoon et al.
(5). However, those were both retrospective studies,
and they may not have actively screened for and
captured hemolysis data, as was done in our study.
Possibly the newer design of the SAPIEN 3 Ultra may
help address this limitation.

use of the CT MAC score to help predict valve

THV PERFORMANCE ENDPOINT. The primary per-

anchoring (14). At 30 days, hemolytic anemia was

formance endpoint of absence of MR grade 2þ or

present in 20% of transseptal cases (3 of 15) but no

greater or mean MV gradient $10 mm Hg was ach-

transatrial cases. There was no correlation with large

ieved in all patients alive with echocardiographic data

paravalvular leak; these 3 patients with hemolytic

available at 1 year. We do not suspect that this is due

anemia had trace paravalvular leak at 30 days and had

to survivorship bias. There were 5 deaths after

none at 1 year. We suspect the higher ﬂow velocity in

30

days.

Three

of

those

subjects

met

THV
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T A B L E 8 Echocardiographic Characteristics at 1 Year

All Patients* (N ¼ 18)

Transatrial Access (n ¼ 8)

Transseptal Access (n ¼ 10)

p Value†

Ejection fraction (%)

65.3 (60.8–69.9)

68.4 (64.4–71.3)

64.5 (60.4–65.5)

0.18

Stroke volume (ml)

89.2 (62.8–94.5)

89.2 (69.9–94.2)

77.7 (60.9–98.9)

1.00

Cardiac output (l/min)

5.1 (4.5–7.4)

5.1 (4.7–6.8)

5.9 (4.4–7.7)

1.00

Mean MVG (mm Hg)

6.1 (5.6–7.1)

6.4 (4.2–7.4)

6.1 (5.7–6.8)

0.93

MVA (cm2)‡
Pulmonary artery systolic pressure (mm Hg)§

3.1 (2.6–3.9)

2.6 (2.3–3.0)

3.8 (3.0–4.1)

0.05

39.3 (35.0–48.3)

37.7 (26.7–48.3)

40.0 (36.8–52.1)

0.46

Peak LVOT gradient

5.3 (3.5–8.4)

6.8 (5.1–9.0)

4.2 (3.5–6.4)

0.27

Mean LVOT gradient

3.1 (2.2–4.9)

3.9 (2.8–5.1)

2.4 (2.2–4.1)

0.48

Severity of total mitral regurgitation
None to trace
1 (þ)
2 (þ)
$3 (þ)

10/18 (55.6)
8/18 (44.4)
0/18 (0)
0/18 (0)

5/8 (62.5)
3/8 (37.5)
0/8 (0)
0/8 (0)

5/10 (50.0)
5/10 (50.0)
0/10 (0)
0/10 (0)

Severity of paravalvular mitral regurgitation
None to trace
1 (þ)
2 (þ)
$3 (þ)

16/18 (88.9)
2/18 (11.1)
0/18 (0)
0/18 (0)

8/8 (100.0)
0/8 (0.0)
0/8 (0)
0/8 (0)

8/10 (80.0)
2/10 (20.0)
0/10 (0)
0/10 (0)

0.66

0.48

Values are median (interquartile range) or n/N (%). *At 1 yr, 18 echocardiographic studies were available: 10 patients died, 1 withdrew consent 8 days after transatrial TMVR, 1
withdrew consent 187 days after transatrial TMVR, and 1 patient alive at 1 yr did not have a 1-yr follow-up visit. †Transatrial vs. transseptal. ‡Uncertain reliability; standard
echocardiographic methods are validated in rheumatic disease and not for MAC or after TMVR. §5 missing values.
Abbreviations as in Tables 2, 3, and 5.

performance endpoint at 30 days and 2 did not

disease on day 355 post-ViMAC. The latter underwent

because of MR grade 2þ. These 2 subjects died of

1-year

noncardiovascular causes, subdural hematoma after

prior to his death, which showed a mean MV gradient

head trauma subsequent to a fall, and end-stage renal

of 5.8 mm Hg and 1þ MR, meeting the performance

follow-up

transthoracic

echocardiography

F I G U R E 4 6-Min Walk Test

IQR ¼ interquartile range.
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F I G U R E 5 Quality-of-Life Score

IQR ¼ interquartile range; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire.

endpoint. These results are encouraging considering

research trials, but the mostly female population is

the round shape of the aortic THV and the oval saddle

similar to that of other prior MAC registry studies

shape of the native MV, which could result in more

(4,5). The reasons for this may be multifactorial,

residual paravalvular leak. Although the mean MV

including a higher prevalence of MAC in women and

gradient was higher than reported in THV designed

higher surgical risk, resulting in women’s being

for the mitral position (6.1  1.6 mm Hg vs. 3.0 

referred more often for TMVR.

1.1 mm Hg), the amount of residual MR was

STUDY LIMITATIONS. First, this was an early feasi-

similar (11).

bility study with a small number of patients enrolled.

FEMALE SEX. Most of the patients included in this

Because it was not randomized and controlled, the

study were women (71%), unlike in many other

results cannot provide evidence that MV intervention

F I G U R E 6 Mean Mitral Valve Gradient
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in patients with advanced MV dysfunction attribut-

support from Abbott Vascular and Edwards Lifesciences. Dr. Wang

able to MAC is associated with decreased mortality.

has served as a consultant for Edwards Lifesciences, Boston Scienti-

Similarly, assignment to access type was not randomized; therefore, difference in outcomes among

ﬁc, Materialise, and HighLife Medical; and has received grant support
from Boston Scientiﬁc. Dr. Salinger has served as a proctor for Boston
Scientiﬁc and Edwards Lifesciences. Dr. Kodali has served as a

access types can only generate hypotheses. In addi-

consultant for Admedus, Meril Lifesciences, Abbott Vascular, Jena-

tion, outcomes of patients who were not accepted in

Valve, and Claret Medical; and has ownership interest in Dura

the trial were not collected. Therefore, data on the
natural history of these patients is unknown.

Biotech, Thubrikar Aortic Valve, Microinterventional Devices, and
Supira Medical. Dr. George has served as a consultant for Boston
Scientiﬁc, Medtronic, Edwards Lifesciences, and W.L. Gore & Asso-

Second, the outcomes of septal ablation procedures performed outside the trial in preparation for
possible patient enrollment were not collected. Pa-

ciates. Dr. Bapat has served as a consultant for Edwards Lifesciences,
Medtronic, and Sorin. Dr. Meduri has served as a consultant for
Medtronic and Boston Scientiﬁc; and has served on the advisory
board for Boston Scientiﬁc. Dr. Tang is a physician proctor for Med-

tients may have undergone alcohol septal ablation

tronic; and is a consultant for Medtronic, Abbott Structural Heart, and

that resulted in poor outcomes, and their cases were

W.L. Gore & Associates. Dr. Reisman has served as a consultant for

never presented for enrollment in this study. Alcohol

Edwards Lifesciences. Dr. Feldman is an employee of Edwards Lifesciences. Dr. Hahn has received speaker fees from Baylis Medical,

septal ablation was the only LVOTO risk reduction

Edwards Lifesciences, and Medtronic; is a consultant for Abbott

strategy used in transseptal cases. Percutaneous

Structural Heart, Edwards Lifesciences, W.L. Gore & Associates,

laceration of the anterior leaﬂet with the LAMPOON

Medtronic, Navigate, and Philips Healthcare; has received nonﬁnan-

procedure was developed after the MITRAL trial was

cial support from 3mensio Medical Imaging; holds equity in Navigate;
and is the chief scientiﬁc ofﬁcer for the Echocardiography Core Lab-

initiated and not used in this study. Therefore, safety

oratory at the Cardiovascular Research Foundation for multiple

of these 2 important strategies was not compared.

industry-sponsored trials, for which she receives no direct industry

Finally, the patient population in our study was
highly selected, with the initial screen failure rate at 2
to 1. Therefore, our results cannot be applied to the

compensation. Dr. O’Neill has served as a consultant for Abiomed,
Boston Scientiﬁc, and Edwards Lifesciences. All other authors have
reported that they have no relationships relevant to the contents of
this paper to disclose.

general population.
NEXT STEPS. Further studies are needed to reﬁne the

patient selection process and standardize the transseptal ViMAC technique. The MITRAL II pivotal trial
will evaluate the safety and effectiveness of transseptal

ViMAC

with

the

SAPIEN

3

Ultra

THV

ADDRESS FOR CORRESPONDENCE: Dr. Mayra Guer-

rero, Mayo Clinic College of Medicine, Department of
Cardiovascular Medicine, Mayo Clinic Hospital, 1216
2nd Street SW, Rochester, Minnesota 55905, USA.
E-mail: mayraguerrero@icloud.com.

(NCT04408430) in patients at high surgical risk.

CONCLUSIONS
ViMAC was associated with signiﬁcant alleviation of
symptoms and improvement in quality of life as well
as stable THV performance at 1 year. TMVR-induced
LVOTO can be prevented with pre-emptive alcohol
septal ablation in patients at risk. In patients treated
with transseptal access, 30-day mortality was lower
than predicted by the Society of Thoracic Surgeons
score, and 1-year mortality was similar to that re-

PERSPECTIVES
WHAT IS KNOWN? Patients with severe MAC often
have high surgical risk. TMVR is emerging as an
alternative for these patients.
WHAT IS NEW? High-risk patients with severe MAC
and MV dysfunction who were treated with a ViMAC
procedure had signiﬁcant reduction of symptoms and
improvement in quality of life, as well as stable THV

ported for transcatheter MV repair and replacement

performance at 1 year. Alcohol septal ablation per-

populations. Further studies are needed to evaluate

formed 3 to 4 weeks before TMVR can decrease the

the safety and efﬁcacy of ViMAC.

risk for TMVR-induced LVOTO and facilitate safe
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